Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma

Figures & data

Table 1 The comparative efficacy of second-line agents in MCL (data from select Phase II trials)

Clinical trials in relapsed or refractory MCL	N	PR	CR	ORRa	Significant AEb
Bortezomib^Citation21	141	26% (36/141)	6% (9/141)	47%	Fatigue, thrombocytopenia, neuropathy
Bortezomib^Citation22	28	43% (12/28)	0	46.4%
Bortezomib^Citation23	29	21% (6/29)	21% (6/29)	41% (12/29)
Bortezomib^Citation24	10	40% (4/10)	0	50% (5/10)
Lenalidomide^Citation30	15	33% (5/15)	20% (3/15)	53% (8/15)	Neutropenia, leucopenia, thrombocytopenia
Thalidomide^Citation29	16	50% (8/16)	25% (4/16)	81% (13/16)	Somnolence, neuropathy, constipation
Bendamustine + fludarabine^Citation25	9	66% (6/9)	33% (3/9)	100% (9/9)	Leukopenia, neutropenic fever, thrombocytopenia, anemia
Bendamustine + rituximab^Citation26	16	25% (4/16)	50% (8/16)	75% (12/16)
Bendamustine + rituximab + mitoxantrone^Citation28	18	44% (8/18)	33% (6/18)	78% (14/18)
Temsirolimus^Citation31	27	37% (10/27)	4% (1/27)	41% (11/27)	Thrombocytopenia, fatigue, hyperglycemia, dyspnea
Temsirolimus^Citation32	34	35% (12/34)	3% (1/34)	38% (13/34)

Notes:

a ORR based on PR and CR.

b Generally grade 3 or higher.

Abbreviations: N, number of patients with MCL evaluable for efficacy; PR, partial response; CR, complete response; ORR, overall response rate; AE, adverse events.

Figure 1 Intracellular proteins involved in the PI3K/Akt/mTOR pathway.

FisherRIBernsteinSHKahlBSMulticenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaJ Clin Oncol2006244867487417001068

 PubMed Web of Science ®Google Scholar

BelchAKouroukisCTCrumpMA phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150Ann Oncol20071811612116971665

 PubMed Web of Science ®Google Scholar

GoyAYounesAMcLaughlinPPhase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphomaJ Clin Oncol20052366767515613697

 PubMed Web of Science ®Google Scholar

O’ConnorOAWrightJMoskowitzCPhase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphomaJ Clin Oncol20052367668415613699

 PubMed Web of Science ®Google Scholar

HabermannTMLossosISJusticeGLenalidomide oral mono-therapy produces a high response rate in patients with relapsed or refractory mantle cell lymphomaBr J Haematol200914534434919245430

 PubMed Web of Science ®Google Scholar

KaufmannHRadererMWohrerSAntitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphomaBlood20041042269227115166030

 PubMed Web of Science ®Google Scholar

KoenigsmannMKnaufWHeroldMFludarabine and bendamustine in refractory and relapsed indolent lymphoma – a multicenter phase I/II trial of the East German Society of Hematology And Oncology (OSHO)Leuk Lymphoma2004451821182715223642

 PubMed Web of Science ®Google Scholar

RummelMJAl-BatranSEKimSZBendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphomaJ Clin Oncol2005233383338915908650

 PubMed Web of Science ®Google Scholar

WeideRHessGKopplerHHigh anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)Leuk Lymphoma2007481299130617613757

 PubMed Web of Science ®Google Scholar

AnsellSMInwardsDJRowlandKMJrLow-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupCancer200811350851418543327

 PubMed Web of Science ®Google Scholar

WitzigTEGeyerSMGhobrialIPhase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphomaJ Clin Oncol2005235347535615983389

 PubMed Web of Science ®Google Scholar